Neuland Laboratories Limited is engaged in the manufacturing and sale of bulk drugs and active pharmaceutical ingredients (APIs) with exports to over 35 countries.

The company reported exceptional growth in Q2 FY26 with a revenue increase of 63.7% compared to the same period last year, largely driven by their CMS projects.

Neuland is expanding its peptide manufacturing capacity with a new four-module facility, demonstrating its commitment to catering to high-demand segments in the pharmaceutical industry.

The company's strategic joint venture with API Corporation, Japan, reflects its efforts to expand and strengthen its global manufacturing and distribution capabilities.

Challenges include high working capital, inventory management, and dependency on specific commercial molecules for growth, highlighting the need for diversification.